Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Penumbra, Inc. Common Stock (NY:PEN)

337.77 -1.20 (-0.35%)
Streaming Delayed Price Updated: 10:14 AM EST, Feb 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Penumbra, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
$100 Invested In Penumbra 10 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Peering Into Penumbra Inc's Recent Short Interest ↗
 
Via Benzinga
News headline image
Merit Medical Systems, ICU Medical, and Penumbra Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after the U.S. Commerce Department initiated a national security investigation into medical equipment and devices, raising concerns about potential... 
Via StockStory
Topics World Trade
News headline image
Here's How Much $100 Invested In Penumbra 10 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
1 High-Flying Stock to Own for Decades and 2 We Turn Down
"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the premium, they typically experience elevated... 
Via StockStory
News headline image
What Does the Market Think About Penumbra? ↗
 
Via Benzinga
News headline image
Expert Outlook: Penumbra Through The Eyes Of 7 Analysts ↗
 
Via Benzinga
News headline image
Oscar Health, Penumbra, DexCom, Merit Medical Systems, and HCA Healthcare Shares Are Falling, What You Need To Know
A number of stocks fell in the afternoon session after markets pulled back, reversing early gains, as investor sentiment remained cautious despite a softer-than-expected inflation reading. 
Via StockStory
Topics Economy
News headline image
3 Healthcare Stocks We’re Skeptical Of
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory... 
Via StockStory
Topics Stocks
News headline image
3 Mid-Cap Stocks We Steer Clear Of
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from... 
Via StockStory
News headline image
Earnings Scheduled For July 29, 2025 ↗
 
Via Benzinga
News headline image
This Accenture Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday ↗
 
Via Benzinga
News headline image
This Unisys Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗
 
Via Benzinga
News headline image
Deep Dive Into Penumbra Stock: Analyst Perspectives (9 Ratings) ↗
 
Via Benzinga
News headline image
This Penumbra Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday ↗
 
Via Benzinga
News headline image
Spotting Winners: Penumbra (NYSE:PEN) And Medical Devices & Supplies - Cardiology, Neurology, Vascular Stocks In Q2
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at medical devices & supplies - cardiology,... 
Via StockStory
News headline image
3 Cash-Heavy Stocks We Keep Off Our Radar
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining... 
Via StockStory
News headline image
Penumbra, STAAR Surgical, CONMED, Acadia Healthcare, and Select Medical Shares Are Soaring, What You Need To Know
A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer... 
Via StockStory
Topics Economy
News headline image
PEN Q2 Deep Dive: Sales Force Expansion and Clinical Milestones Drive Outperformance
Medical device company Penumbra (NYSE:PEN) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 13.4% year on year to $339.5 million. The company’s full-year revenue... 
Via StockStory
News headline image
1 Safe-and-Steady Stock with Promising Prospects and 2 We Question
Low-volatility stocks may offer stability, but that often comes at the cost of slower growth and the upside potential of more dynamic companies. 
Via StockStory
News headline image
Penumbra PEN Q2 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
3 Cash-Producing Stocks Walking a Fine Line
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
News headline image
Penumbra (PEN) Q2 Revenue Jumps 13% ↗
Via The Motley Fool
News headline image
Penumbra (PEN) Shares Skyrocket, What You Need To Know
Shares of medical device company Penumbra (NYSE:PEN) jumped 11.8% in the afternoon session after the company reported impressive second-quarter financial results that surpassed analyst expectations and... 
Via StockStory
Topics ETFs Stocks World Trade
News headline image
Teradyne, Littelfuse, Marvell Technology, Cheesecake Factory And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Penumbra’s (NYSE:PEN) Q2: Strong Sales, Stock Soars
Medical device company Penumbra (NYSE:PEN) announced better-than-expected revenue in Q2 CY2025, with sales up 13.4% year on year to $339.5 million. The company’s full-year revenue guidance of $1.36... 
Via StockStory
News headline image
Penumbra Inc (NYSE:PEN) Surpasses Q2 2025 Earnings and Revenue Estimates Amid Market Challenges ↗
Penumbra Inc (NYSE:PEN) beat Q2 2025 revenue and EPS estimates, reporting $339.46M and $0.86, driven by strong demand for its thrombectomy and vascular intervention tech. 
Via Chartmill
News headline image
Penumbra (PEN) To Report Earnings Tomorrow: Here Is What To Expect
Medical device company Penumbra (NYSE:PEN) will be reporting earnings this Tuesday after market hours. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence
News headline image
NeoGenomics, RadNet, Pediatrix Medical Group, Penumbra, and Neogen Shares Plummet, What You Need To Know
A number of stocks fell in the afternoon session after the U.S. administration announced a sharp escalation in trade tensions by threatening new tariffs on Canada. 
Via StockStory
Topics ETFs Stocks World Trade
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.